News: Brokerage

Ardigo and Caruso of CBRE represent tenant in 149,000 s/f lease

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, has signed a 10-year, 149,000 s/f lease at The Landmark at Eastview, located at 765 Old Saw Mill River Rd. where it has been headquartered for over a decade. Patricia Ardigo, first VP and director of CB Richard Ellis' life sciences group, and Robert Caruso, senior managing director of its Westchester/Fairfield operation, represented Progenics. Bill Kane, director of leasing & acquisitions for the property's management, BioMed Realty Trust, Inc., represented the owner, BMR-Landmark at Eastview, LLC. "The Landmark at Eastview is known for its natural setting, distinctive architecture and sophisticated research and development facilities," said Ardigo. "Progenics opted to sign a new lease as the facilities have proven to be the ideal environment to support the firm's research and growth." The Landmark at Eastview is a 1,111,000 s/f multi-tenanted science park comprised of research, manufacturing and office space in central of Westchester County. The life science complex recently added a 360,000 s/f, three-building addition to its original/existing 751,000 rentable s/f. The property's prime location provides easily access to 1-287, 1-87, the Saw Mill River Pwy., Sprain Brook Pwy., Bronx River Pwy., and Hutchinson River Pwy., and is in close proximity to Metro North's White Plains and Tarrytown train stations.
MORE FROM Brokerage

NYSCAR June 2026 president’s message - by Mercedes Brien

As I write this letter, we are preparing to be at the Annual Conference being held at the Rivers Casino, Schenectady, New York. I look forward to reporting on the conference in my next letter. We have some great courses coming up via Zoom. Please be sure to keep watch on upcoming courses by visiting nyscar.org/resources and tools/professional development.
READ ON THE GO
DIGITAL EDITIONS
Subscribe
Columns and Thought Leadership
The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

The death of the generic offering memorandum: What buyers expect in 2025 - by Kimberly Zar Bloorian

There was a time when an offering memorandum (OM) was pretty bare bones, some photos, a few bullet points on income, and a rent roll thrown in at the back. That used to get the job done. Not anymore. In 2025, buyers are sharper, faster, and more selective. They’re looking
The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

The anticipated effect of Basel III and ISO 20022 implementation on commercial real estate - by Michael Zysman

July 1, 2025 is the deadline for US banks to begin to adopt Basel III banking standards and July 14, 2025 is the deadline for U.S. banks to adopt ISO 20022 messaging standards. Both will have a significant effect on the banking and commercial real estate (CRE) finance sectors.
A fresh start - by Shallini Mehra and Amit Doshi

A fresh start - by Shallini Mehra and Amit Doshi

For the past several years, the New York City multifamily housing market has been defined by disruption. The combined impact of the HSTPA rent laws and a sharply higher interest rate environment has fundamentally reduced
Tri-state capital  migrates nationally amid  regulation pressure - by Reese Weaver

Tri-state capital migrates nationally amid regulation pressure - by Reese Weaver

New York tri-state multifamily investors are increasingly reallocating capital to less-regulated markets across the U.S. as rent control and legislative risk erode returns at home. With over 60% of New York City’s rental housing stock classified as rent-stabilized, the traditional value-add model — buying under-performing buildings,